Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2212 (LINC02212) is a long non-coding RNA (lncRNA) that does not encode a protein and is transcribed from intergenic regions of the genome[1][5]. LINC02212 is implicated in the regulation of gene expression, most notably by acting as an enhancer, recruiting transcription factors, and regulating alternative splicing events[3]. It displays altered expression levels in several cancer types, particularly cholangiocarcinoma, kidney renal clear cell carcinoma, and kidney renal papillary cell carcinoma, where it is found to be upregulated in tumor tissue compared to normal tissue[3]. While long intergenic non-coding RNAs in general are known to participate in various aspects of cellular regulation, the specific functional or therapeutic targeting and detailed mechanisms for LINC02212 remain largely uncharacterized in current public data[1][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2212 (LINC02212).